Sage Therapeutics (NSDQ:SAGE) said today that the FDA accepted its new drug application for an intravenous formulation of brexanolone as a treatment for postpartum depression.
The application was accepted under priority review status, according to the Cambridge, Mass.-based company. If approved, the drug would be the first therapy specifically indicated to treat postpartum depression – the most common medical complication of childbirth.
Get the full story at our sister site, Drug Delivery Business News.
The post Sage Therapeutics wins priority review for intravenous postpartum depression drug appeared first on MassDevice.
from MassDevice https://ift.tt/2ISLVng
Cap comentari:
Publica un comentari a l'entrada